Last reviewed · How we verify

NCT07370142: SPG-PRF

Sphenopalatine Ganglion Pulsed Radiofrequency Treatment Outcomes

Completed NA Last updated 18 March 2026
What this trial tests

NA trial testing Pulsed Radiofrequency of the Sphenopalatine Ganglion in Migraine Disorders, Facial Pain Disorder, Cluster Headache, Trigeminal Neuralgia, Trigeminal Autonomic Cephalalgias in 55 participants. Completed in 1 January 2026.

Timeline
20 March 2025
Primary endpoint
1 October 2025
1 January 2026

Quick facts

Lead sponsorAnkara City Hospital Bilkent
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment55
Start date20 March 2025
Primary completion1 October 2025
Estimated completion1 January 2026
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Ankara City Hospital Bilkent

Who can join

18 and older, any sex, with Migraine Disorders, Facial Pain Disorder, Cluster Headache, Trigeminal Neuralgia, Trigeminal Autonomic Cephalalgias. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose of the Study: This study aims to evaluate the clinical effectiveness and long-term outcomes of "Sphenopalatine Ganglion (SPG) Pulsed Radiofrequency (PRF)" treatment in patients with chronic headaches and facial pain. The SPG is a major neural junction for craniofacial pain signaling. PRF is a safe, minimally invasive technique that modulates pain transmission without causing thermal damage to the nerve tissue. Methodology: The study will include 55 volunteer patients at the Ankara Bilkent City Hospital Algology Clinic who are unresponsive to medical treatments. Patients will undergo the standard "fluoroscopy-guided infrazygomatic approach." Pain intensity (VAS), quality of life, patient satisfaction, and changes in analgesic consumption will be recorded at baseline and during follow-up visits at 1 week, 1 month, 3 months, and 6 months post-procedure using various clinical parameters. Expected Benefits and Risks: The research intends to provide evidence regarding the 6-month long-term impact of this intervention on pain scores and patient well-being. Since the study follows routine clinical practices, it poses no additional risks to participants and aims to optimize future treatment strategies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07370142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing